Bristol-Myers Squibb BuSpar
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Marketing exclusivity for buspirone tablets extended through Nov. 22 on the basis of pediatric studies requested by FDA. The pediatric data was submitted in an sNDA that FDA found "approvable" Aug. 2